|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Trade accounts receivable, net of allowance for credit losses of $4 and $17, respectively | ||||||||||||||||||||
| Inventories, current | ||||||||||||||||||||
| Deferred transaction costs | ||||||||||||||||||||
| Income taxes receivable | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Deferred transaction costs | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Inventories, noncurrent | ||||||||||||||||||||
| Other noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and shareholders' deficit | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Accrued expense | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Legacy SMAP promissory notes | ||||||||||||||||||||
| Related party | ||||||||||||||||||||
| Legacy SMAP | ||||||||||||||||||||
| Total legacy SMAP promissory notes | ||||||||||||||||||||
| Right-of-use liabilities, current | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Contract liabilities, noncurrent | ||||||||||||||||||||
| Convertible notes, noncurrent | ||||||||||||||||||||
| Right-of-use liabilities, noncurrent | ||||||||||||||||||||
| Warrants | ||||||||||||||||||||
| Deferred tax liabilities, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025, and 2,218,278 and 2,007,613 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...